{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:51:08Z","timestamp":1790398268378,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) retinitis has been increasingly reported in patients receiving Janus kinase (JAK) inhibitors, yet vision-threatening ischemic complications in this population remain poorly characterized. Immune recovery uveitis (IRU) and cystoid macular edema (CME) are recognized post-infectious sequelae, but delayed retinal ischemia and hemorrhage in the setting of JAK inhibition are uncommon. We present a case that illustrates these complications in a patient on upadacitinib for rheumatoid arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>An 81-year-old woman with rheumatoid arthritis on upadacitinib for approximately one year and long-term hydroxychloroquine presented with decreased vision and floaters in her left eye. Examination revealed vitritis, focal hemorrhagic retinitis, and an epiretinal membrane without CME. Anterior chamber paracentesis confirmed CMV infection via aqueous humor polymerase chain reaction, guiding prompt antiviral therapy. She received oral valganciclovir and alternating intravitreal ganciclovir and foscarnet, though systemic therapy was later discontinued due to leukopenia. After cessation of upadacitinib and hydroxychloroquine, the retinitis stabilized, but she developed IRU with new-onset CME. Weeks later, she presented with a dense vitreous hemorrhage without retinal tears or detachment. Fluorescein angiography revealed temporal retinal ischemia remote from the original retinitis. Intravitreal bevacizumab led to improvement in both CME and hemorrhage. Pan-retinal photocoagulation is planned to reduce the risk of recurrent hemorrhage.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case illustrates CMV retinitis in the setting of JAK inhibition complicated by delayed retinal ischemia and vitreous hemorrhage arising remote from the original retinitis. Although ischemic vasculopathy is a recognized complication of CMV retinitis among non-HIV immunosuppressed patients, such sequelae have been infrequently documented in JAK inhibitor-associated cases. Ophthalmologists should maintain a high index of suspicion for CMV retinitis in this emerging population and continue close surveillance for delayed ischemic complications even after apparent disease stabilization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-025-04558-y","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T15:45:30Z","timestamp":1768232730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["From infection to infarction: cytomegalovirus retinitis complicated by retinal ischemia and vitreous hemorrhage in the setting of JAK inhibition - a case report"],"prefix":"10.1186","volume":"26","author":[{"given":"Ciera D.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulwa","family":"El Zein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Yamanuha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"4558_CR1","doi-asserted-by":"crossref","unstructured":"Kraev K, Geneva-Popova MG, Hristov BK, Uchikov PA, Belova-Popova SD, Kraeva MI, et al. Examining the safety profile of Janus kinase (JAK) inhibitors in the management of immune-mediated diseases: a comprehensive review. Life (Basel) [Internet]. 2023;13(12). Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10744491\/#sec1-life-13-02244","DOI":"10.3390\/life13122244"},{"key":"4558_CR2","doi-asserted-by":"crossref","unstructured":"Adas MA, Alveyn E, Cook E, Dey M, Galloway JB, Bechman K. The infection risks of JAK inhibition. Expert Rev Clin Immunol [Internet]. 2022;18(3):253\u201361. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8935945\/","DOI":"10.1080\/1744666X.2022.2014323"},{"key":"4558_CR3","doi-asserted-by":"crossref","unstructured":"Mansilla-Polo M, Morgado-Carrasco D. Biologics versus JAK inhibitors. Part II: risk of infections. A narrative review. Dermatol Ther (Heidelb) [Internet]. 2024;14(8):1983\u20132038. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/39014279\/","DOI":"10.1007\/s13555-024-01203-2"},{"key":"4558_CR4","doi-asserted-by":"crossref","unstructured":"Munro M, Yadavalli T, Fonteh C, Arfeen S, Lobo-Chan A-M. Cytomegalovirus retinitis in HIV and non-HIV individuals. Microorganisms [Internet]. 2019;8(1):55. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7022607\/#sec1-microorganisms-08-00055","DOI":"10.3390\/microorganisms8010055"},{"key":"4558_CR5","doi-asserted-by":"crossref","unstructured":"Zhang J, Kamoi K, Zong Y, Yang M, Zou Y, Miyagaki M, et al. Cytomegalovirus retinitis: clinical manifestations, diagnosis and treatment. Viruses [Internet]. 2024;16(9):1427. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11437412\/","DOI":"10.3390\/v16091427"},{"key":"4558_CR6","doi-asserted-by":"crossref","unstructured":"Yanagisawa K, Ogawa Y, Hosogai M, Todokoro D, Mitsui T, Yokohama A, et al. Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy. J Infect Chemother [Internet]. 2017;23(8):572\u20135. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/28389165\/","DOI":"10.1016\/j.jiac.2017.03.002"},{"key":"4558_CR7","doi-asserted-by":"crossref","unstructured":"Cugley DR, Darby J, Lim LL. Tofacitinib-associated cytomegalovirus retinitis. Lara D Veeken [Internet]. 2020;59(9):e35\u20137. Available from: https:\/\/academic.oup.com\/rheumatology\/article-abstract\/59\/9\/e35\/5716650?redirectedFrom=fulltext","DOI":"10.1093\/rheumatology\/kez681"},{"key":"4558_CR8","doi-asserted-by":"crossref","unstructured":"Hirai H, Akai Y, Ogata N, Ueda T. Cytomegalovirus retinitis in a patient taking upadacitinib: a case report. Cureus [Internet]. 2023;15(11):e48337. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10698290\/#REF12","DOI":"10.7759\/cureus.48337"},{"key":"4558_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.4103\/ijo.ijo_1117_25","volume":"73","author":"P Dutta Majumder","year":"2025","unstructured":"Dutta Majumder P, Kene RD. Intraocular infections following biologicals and Janus kinase inhibitors. Indian J Ophthalmol. 2025;73:1091\u20134. https:\/\/doi.org\/10.4103\/ijo.ijo_1117_25.","journal-title":"Indian J Ophthalmol"},{"key":"4558_CR10","doi-asserted-by":"publisher","unstructured":"Cho J, Siegel N, Subramanian ML, et al. Rapidly progressive neovascular glaucoma from cytomegalovirus retinitis in a non\u2013human immunodeficiency virus patient. RETINAL Cases; Brief Reports. 2021;15:62\u20134. https:\/\/doi.org\/10.1097\/icb.0000000000000734","DOI":"10.1097\/icb.0000000000000734"},{"key":"4558_CR11","doi-asserted-by":"crossref","unstructured":"Teoh SC, Wang PX, Wong EPY. The epidemiology and incidence of cytomegalovirus retinitis in the HIV population in Singapore over 6 years. Investigative Ophthalmology & Visual Science [Internet]. 2012;53(12):7546. Available from: https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2127166","DOI":"10.1167\/iovs.12-10349"},{"key":"4558_CR12","unstructured":"Yamanuha J. The Case of the Mysterious Curtain. American Academy of Ophthalmology [Internet]. Available from: https:\/\/www.aao.org\/eyenet\/article\/case-of-mysterious-curtain#:~:text=At%20age%2083%2C%20Mae%20Morris,vision%20in%20her%20right%20eye"},{"key":"4558_CR13","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/xzgaoy","author":"J-Y Lee","year":"2022","unstructured":"Lee J-Y, Kim SH, Lee S-H, et al. Effect of Janus kinase inhibitors on T cell responses to herpes Zoster in rheumatoid arthritis patients. Clin Experimental Rheumatol Published Online First: 19 April. 2022. https:\/\/doi.org\/10.55563\/clinexprheumatol\/xzgaoy.","journal-title":"Clin Experimental Rheumatol Published Online First: 19 April"},{"key":"4558_CR14","doi-asserted-by":"publisher","unstructured":"Hawerkamp HC, Domdey A, Radau L, et al. Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation. Arthritis Res Therapy. 2021;23. https:\/\/doi.org\/10.1186\/s13075-021-02509-8.","DOI":"10.1186\/s13075-021-02509-8"},{"key":"4558_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/eji.202149361","volume":"52","author":"C Cenac","year":"2021","unstructured":"Cenac C, Ducatez MF, Gu\u00e9ry J. Hydroxychloroquine inhibits proteolytic processing of endogenous TLR7 protein in human primary plasmacytoid dendritic cells. Eur J Immunol. 2021;52:54\u201361. https:\/\/doi.org\/10.1002\/eji.202149361.","journal-title":"Eur J Immunol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04558-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04558-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04558-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:22:05Z","timestamp":1768342925000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-025-04558-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4558"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04558-y","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"IRB review was requested, and the institutional review board determined that formal approval was not required for this single-patient case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of their personal and clinical details, along with any identifying images. The patient provided consent voluntarily.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"20"}}